Developing the next generation of antibody drug conjugates
Drug Target Review
APRIL 22, 2024
Despite excellent pharmacokinetic and stable antibody-linker connections, such ADCs have yet to receive market approval. Site-specific conjugations often necessitate the re-engineering of antibody sequencing to introduce amino acid with a reactive functional group. This approach offers the advantage of using chemical modification.
Let's personalize your content